Evidence Base

DRX9000 Research: What We Know and How Reliable It Is

We present each study as its authors report it, together with its design, sample size, and limitations, so you can judge the strength of every result for yourself.

How to Read the Data

Levels of Evidence

Not all studies are equally convincing. The highest level of evidence comes from randomized controlled trials: patients are randomly assigned to the new method or a comparison, which rules out many sources of bias. Comparative and cohort studies rank lower, and case series without a control group and individual case reports rank lower still.

Most DRX9000 studies are observational: retrospective chart reviews, uncontrolled case series, and case reports. There are no randomized controlled trials of the DRX9000 among them yet. Many studies were funded by the manufacturer or involved its employees. We note this for each study.

A 2006 systematic review (partly funded by Axiom Worldwide) of motorized decompression devices as a class concluded that their effectiveness for chronic discogenic pain remains unproven. Later DRX9000 studies report reduced pain and increased disc height, but without control groups. That is why we do not present these results as a guarantee and do not generalize them to all patients.

FDA clearance. The DRX9000 is FDA-cleared (510(k)), K060735, 2006. The 510(k) process confirms that a device is substantially equivalent to previously cleared predicate devices. It is a regulatory status, not a clinical study of effectiveness.

Clinical Data from Russia

DRX in Russia: Treatment Outcomes in 172 Patients

Clinical material from a Russian clinic, prepared for the journal “Neurosurgery” (Neirokhirurgiya): treatment of lumbar disc herniations on the DRX9000. The DRX9000 method has been used in Russia since 2006, and the DRX9500 since 2008.

97.6%of patients improved to some degree
172patients with lumbar disc herniations completed a DRX9000 course
60.6%significant improvement or virtually complete clinical remission
+12.5%increase in intervertebral space, confirmed under fluoroscopy

Details

How These Results Were Obtained

Patients. 172 patients with disc herniations: L5–S1 58.2%, L4–L5 25.8%, two levels 16.8%, and single cases at L2–L3 and L1–L2. Sensory deficits were present in 90.6% and signs of muscle paresis in 64.2%.

Course. At least 20 DRX9000 sessions; patients with herniations at two levels (19) received a double course of 40 sessions.

Outcomes (as reported by the authors):

significant improvement or virtually complete clinical remission — 101 patients (60.6%), including complete resolution of neurological and orthopedic signs in 49 patients (29.4%);
moderate improvement — 43 patients (25.8%);
slight improvement — 24 patients (14.4%);
no change — 4 patients (2.4%).

Long-term follow-up. 9 patients returned (8 months to 1.5 years later); none had a recurrence of neurological symptoms, and the visits were for minor muscle-tonic complaints. The authors describe marked regression of severe neurological deficits, including a patient operated on 8 years before treatment.

Cervical spine. 39 patients with C3–C7 herniations were treated on the DRX9500 (DRX5000); the authors give a preliminary analysis and note that the sample is still too small for statistical conclusions.

Clinic data. Departmental Hospital at Tula Station, Russian Railways (chief physician E. G. Suvorov, 2014): per 100 patients treated, 6 showed no effect and 94 became completely pain-free.

Limitations: the article was prepared for the journal “Neurosurgery,” and the copy provided does not name the authors; no control group; percentages as given by the authors. Clinic data are each institution’s own statistics.

Key Figures

The Numbers and Where They Come From

86%treatment success in the Gionis & Groteke study (2003), 219 patientsCase series without a control group; success defined as pain of 0–1 on a 0–5 scale.
92%of patients improved: data from clinics using DRX in post-Soviet countriesInternal ELTECH data, not a randomized study.
267patients in the largest retrospective multicenter analysis (Military Medicine, 2025)No control group; partly sponsored by the manufacturer.
4FDA 510(k) clearances for the DRX family of systemsK022602, K023160, K060735 (DRX9000), K243775 (DRX9000-SL).

Breakdown

Where the 86% Figure Comes From: The Gionis & Groteke Study

The best-known DRX9000 figure is based on this study. Below is what it measured and what it does not prove.

Source. This analysis follows the version of the study in the manufacturer’s materials: Gionis T.A., “Advances in Biotechnology Improve Clinical Outcomes for Spinal Decompression” (a reprint held in the ELTECH archive). The journal publication of the same study (Gionis T.A., Groteke E. Spinal Decompression. Orthopedic Technology Review, November/December 2003) describes some details differently; its full text is on this site. The 86% result (188 of 219 patients) is the same in both versions.

Participants. From more than 500 people who sought care, the researchers selected patients with MRI-confirmed lumbar disc herniation and degeneration, pain rated 3 to 5 on a 0–5 scale, radiation to the legs, and symptoms lasting at least 4 weeks. Patients with prior spinal surgery were excluded. The analysis included 219 people (79 women and 140 men, aged 24–74) who completed at least 10 sessions. The 14 patients who dropped out were not counted.

Treatment. 20 sessions over 6 weeks: daily for 2 weeks, 3 times a week for 2 weeks, and 2 times a week for 2 weeks. Each session lasted 45 minutes on the DRX9000, followed by 15 minutes of cold therapy and interferential current. For the first two weeks, patients wore a lumbar brace, limited their activity, and took a prescribed anti-inflammatory drug (naproxen).

Definition of success. Pain reduced to 0 (no pain) or 1 (occasional pain) with no need for further medication or treatment. 188 of 219 patients, or 86%, reached this outcome. Success rates by subgroup ranged from 68% (multiple herniations without degeneration) to 100% (single herniation with degeneration, 24 patients). By week two, 77% of patients had more than a 50% reduction in low back pain. At the follow-up visit 30 days after the course, 5 patients had a recurrence.

Limitations.

No control group: this is a case series, so the result cannot be compared with another treatment or with the natural course of the condition.
Patients also received an anti-inflammatory drug, cold therapy, electrotherapy, and exercise, so the effect cannot be attributed to the device alone.
Patients who dropped out were excluded from the calculation.
Follow-up ends 30 days after the course. The study did not look at outcomes over several years.
The text contains an internal inconsistency: the narrative lists 34 patients without success, while the table lists 31.
The reprint does not state a funding source. According to a secondary source (a clinic review from 2012), the study was funded by Axiom Worldwide, the former manufacturer of the DRX9000.
The systematic review by Macario and Pergolizzi (2006) classifies this study as a case series without a control group and reports 229 patients in it.

How we use this figure. Only together with the study name, sample size, and success criterion. We do not say “DRX9000 cures 86% of patients,” and we do not extend the result to time frames the study did not examine.

Clinical Practice

Where the 92% Figure Comes From: Clinic Data

92% is the share of patients who improved, according to data from clinics using DRX™ systems in post-Soviet countries. These are internal ELTECH data, accumulated over years of work with partner clinics since 2010.

These data reflect practical experience but are not a clinical study. There is no control group, criteria for improvement may differ between clinics, and no independent verification has been performed. That is why we present this figure separately from scientific publications and do not compare it directly with study results.

Library

Research Library

Studies are listed from newest to oldest. Each entry gives the citation, the authors’ conclusion as published, and a link to the full text of the article on this site.

Clinical Trials in Russia

Clinical Studies for Spinal Decompression System DRX9000™ - Manufactured by Axiom Worldwide, USA (Minukov et al., 2006)

Source: G.N. Minukov, E.V. Vorobiev. Clinical Studies for Spinal Decompression System DRX9000™ - Manufactured by Axiom Worldwide, USA. Conducted in the Neurology Unit of Municipal Clinical Hospital, May 13, 2006 - July 24, 2006. Clinical trial report, English version.

Authors’ conclusion: “The DRX9000™ due to its functionality does not have domestic analogues and considerably exceeds all other devices developed for spinal decompression. The expressed positive clinical effects and tomographic images were demonstrated during treatment of the majority of patients diagnosed with disc herniations at the L5-S1 spinal level. The DRX9000™ spinal decompression system, manufactured by Axiom Worldwide, USA, has sustained clinical trials. We have no negative remarks on the DRX9000™.”